Andrew Zhu on Atezolizumab/Bevacizumab in HCC – The ASCO Post

AACR Virtual Annual Meeting 2020 Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with clinical response or resistance to the combination treatment of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma…

ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer – The ASCO Post

By Jo Cavallo Posted: 4/27/2020 1:24:00 PM Last Updated: 4/27/2020 3:04:49 PM The TRACERx study investigated phylogenetic tracking and minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) profiling following resection in patients with stage I to III…

American Association for Cancer Research (AACR) Annual Meeting | JAMA | JAMA Network

American Association for Cancer Research (AACR) Annual Meeting | JAMA | JAMA Network American Association for Cancer Research (AACR) Annual Meeting Updated 2020 Explore JAMA Network’s collection of articles published online first to coincide with the American Association for Cancer Research’s Annual Meeting. Read More About AACR: The American Association for Cancer…

P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

Dysregulation of the EGFR family member HER2 (human epidermal growth factor receptor 2) plays an important role in many cancers. HER2 exon 20 in-frame insertion mutations occur in 2−4% of non-small cell lung carcinomas (NSCLC). Despite current HER2-directed treatments, no approved therapies exist for patients with cancers harboring HER2 mutations. Unlike other activating mutations, exon 20…